IE
ELDN icon

Israel Englander’s Eledon Pharmaceuticals ELDN Stock Holding History

Israel Englander’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.86M Buy
+979,712
New +$3.56M ﹤0.01% 3244
2026
Q1 		– Sell
-23,788
Closed -$35.9K – 5877
2025
Q4 		$35.9K Buy
+23,788
New +$56.5K ﹤0.01% 5771
2025
Q3 		– Sell
-171,669
Closed -$465K – 6120
2025
Q2 		$465K Sell
171,669
-639,207
-79% -$1.92M ﹤0.01% 4954
2025
Q1 		$2.75M Buy
810,876
+692,015
+582% +$2.85M ﹤0.01% 3470
2024
Q4 		$490K Buy
+118,861
New +$469K ﹤0.01% 4768
2024
Q2 		– Sell
-13,875
Closed -$28.6K – 6029
2024
Q1 		$28.6K Sell
13,875
-8,992
-39% -$16K ﹤0.01% 5772
2023
Q4 		$41.2K Sell
22,867
-4,283
-16% -$5.95K ﹤0.01% 5511
2023
Q3 		$37.2K Sell
27,150
-15,852
-37% -$21.2K ﹤0.01% 5540
2023
Q2 		$58.9K Buy
43,002
+30,397
+241% +$63.4K ﹤0.01% 5442
2023
Q1 		$30K Buy
+12,605
New +$33.8K ﹤0.01% 5768
2022
Q2 		– Sell
-11,951
Closed -$47K – 7087
2022
Q1 		$47K Sell
11,951
-24,291
-67% -$94.2K ﹤0.01% 6411
2021
Q4 		$160K Buy
36,242
+25,693
+244% +$130K ﹤0.01% 6048
2021
Q3 		$65K Sell
10,549
-7,444
-41% -$52K ﹤0.01% 6535
2021
Q2 		$142K Buy
17,993
+3,405
+23% +$32.1K ﹤0.01% 6137
2021
Q1 		$156K Buy
+14,588
New +$220K ﹤0.01% 5576
2017
Q4 		– Sell
-564
Closed -$53K – 3851
2017
Q3 		$53K Buy
+564
New +$46.8K ﹤0.01% 3408
2017
Q1 		– Sell
-142
Closed -$22K – 3561
2016
Q4 		$22K Buy
142
+64
+82% +$12.3K ﹤0.01% 3277
2016
Q3 		$19K Buy
+78
New +$28.5K ﹤0.01% 3215
2016
Q2 		– Sell
-91
Closed -$82K – 3264
2016
Q1 		$82K Sell
91
-163
-64% -$160K ﹤0.01% 3109
2015
Q4 		$359K Buy
254
+163
+179% +$284K ﹤0.01% 2820
2015
Q3 		$153K Buy
+91
New +$187K ﹤0.01% 3190
2014
Q4 		– Sell
-327
Closed -$802K – 3995
2014
Q3 		$802K Buy
+327
New +$929K ﹤0.01% 2452

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Israel Englander's ELDN Position: Q2 2026 in Review

Israel Englander opened a new position in Eledon Pharmaceuticals (ELDN) in Q2 2026: 979,712 shares worth $3.86M. The stake represents ﹤0.01% of the portfolio and ranks #3244 among its holdings. This is a return to the name: Israel Englander previously reported a position in ELDN as recently as Q4 2025.

Israel Englander first reported a position in ELDN in Q3 2014 and has held it in 22 quarters since. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Israel Englander held 979,712 shares of Eledon Pharmaceuticals worth $3.86M as of Q2 2026.
  • Eledon Pharmaceuticals was a new Israel Englander position in Q2 2026.
  • Eledon Pharmaceuticals made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3244 holding.
  • Israel Englander first reported a position in Eledon Pharmaceuticals in Q3 2014 and has held it in 22 quarters since.
  • 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.